312 related articles for article (PubMed ID: 26350530)
21. Comparing aflibercept, bevacizumab, and ranibizumab for DME: analysis of DRCR Protocol T.
Wykoff CC; Hariprasad SM
Ophthalmic Surg Lasers Imaging Retina; 2015 Mar; 46(3):302-5. PubMed ID: 25835307
[No Abstract] [Full Text] [Related]
22. [Anti-VEGF therapy to treat diabetic macular edema].
Takamura Y
Nippon Ganka Gakkai Zasshi; 2014 Sep; 118(9):747-9. PubMed ID: 25318182
[No Abstract] [Full Text] [Related]
23. Updates on the Clinical Trials in Diabetic Macular Edema.
Demirel S; Argo C; Agarwal A; Parriott J; Sepah YJ; Do DV; Nguyen QD
Middle East Afr J Ophthalmol; 2016; 23(1):3-12. PubMed ID: 26957834
[TBL] [Abstract][Full Text] [Related]
24. Anti-VEGF for the management of diabetic macular edema.
Stefanini FR; Badaró E; Falabella P; Koss M; Farah ME; Maia M
J Immunol Res; 2014; 2014():632307. PubMed ID: 24741610
[TBL] [Abstract][Full Text] [Related]
25. Aflibercept: A Review of Its Use in the Management of Diabetic Eye Complications.
Akiyode O; Major J; Ojo A
J Pharm Pract; 2017 Oct; 30(5):534-540. PubMed ID: 27166390
[TBL] [Abstract][Full Text] [Related]
26. Cost-consequence analysis of extended loading dose of anti-VEGF treatment in diabetic macular edema patients.
Ruiz-Moreno JM; de Andrés-Nogales F; Oyagüez I
BMC Ophthalmol; 2020 Sep; 20(1):371. PubMed ID: 32943041
[TBL] [Abstract][Full Text] [Related]
27. Comparative effectiveness of anti-VEGF agents for diabetic macular edema.
Ollendorf DA; Colby JA; Pearson SD
Int J Technol Assess Health Care; 2013 Oct; 29(4):392-401. PubMed ID: 24290332
[TBL] [Abstract][Full Text] [Related]
28. Systemic Safety of Prolonged Monthly Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema: A Systematic Review and Meta-analysis.
Avery RL; Gordon GM
JAMA Ophthalmol; 2016 Jan; 134(1):21-9. PubMed ID: 26513684
[TBL] [Abstract][Full Text] [Related]
29. Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti-Vascular Endothelial Growth Factor Treatment: Outcomes from the Phase 3 Program.
Do DV; Nguyen QD; Vitti R; Berliner AJ; Gibson A; Saroj N; Soo Y; Boyer DS
Ophthalmology; 2016 Apr; 123(4):850-7. PubMed ID: 26832658
[TBL] [Abstract][Full Text] [Related]
30. Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab and/or Bevacizumab May Further Improve Macular Thickness.
Shah CP; Heier JS
Ophthalmic Surg Lasers Imaging Retina; 2016 Sep; 47(9):836-9. PubMed ID: 27631479
[TBL] [Abstract][Full Text] [Related]
31. Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors.
Chong V
Ophthalmologica; 2012; 227 Suppl 1():2-10. PubMed ID: 22517120
[TBL] [Abstract][Full Text] [Related]
32. SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.
Avery RL; Castellarin AA; Steinle NC; Dhoot DS; Pieramici DJ; See R; Couvillion S; Nasir MA; Rabena MD; Maia M; Van Everen S; Le K; Hanley WD
Retina; 2017 Oct; 37(10):1847-1858. PubMed ID: 28106709
[TBL] [Abstract][Full Text] [Related]
33. Changes in Blood Pressure and Urine Albumin-Creatinine Ratio in a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema.
Glassman AR; Liu D; Jampol LM; Sun JK;
Invest Ophthalmol Vis Sci; 2018 Mar; 59(3):1199-1205. PubMed ID: 29625440
[TBL] [Abstract][Full Text] [Related]
34. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.
Zehetner C; Kirchmair R; Huber S; Kralinger MT; Kieselbach GF
Br J Ophthalmol; 2013 Apr; 97(4):454-9. PubMed ID: 23385630
[TBL] [Abstract][Full Text] [Related]
35. Determinants in Initial Treatment Choice for Diabetic Macular Edema.
VanderBeek BL; Scavelli K; Yu Y
Ophthalmol Retina; 2020 Jan; 4(1):41-48. PubMed ID: 31345726
[TBL] [Abstract][Full Text] [Related]
36. Using Patient-Level Data to Develop Meaningful Cross-Trial Comparisons of Visual Impairment in Individuals with Diabetic Macular Edema.
Sivaprasad S; Regnier SA; Fajnkuchen F; Wright J; Berger AR; Mitchell P; Larsen M
Adv Ther; 2016 Apr; 33(4):597-609. PubMed ID: 26951552
[TBL] [Abstract][Full Text] [Related]
37. Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema: a report by the American Academy of Ophthalmology.
Ho AC; Scott IU; Kim SJ; Brown GC; Brown MM; Ip MS; Recchia FM
Ophthalmology; 2012 Oct; 119(10):2179-88. PubMed ID: 22917890
[TBL] [Abstract][Full Text] [Related]
38. Anti-vascular endothelial growth factor drug treatment of diabetic macular edema: the evolution continues.
Stewart MW
Curr Diabetes Rev; 2012 Jul; 8(4):237-46. PubMed ID: 22515701
[TBL] [Abstract][Full Text] [Related]
39. Intravitreal Aflibercept for Patients With Diabetic Macular Edema Refractory to Bevacizumab or Ranibizumab: Analysis of Response to Aflibercept.
Chen YY; Chang PY; Wang JK
Asia Pac J Ophthalmol (Phila); 2017; 6(3):250-255. PubMed ID: 28436640
[TBL] [Abstract][Full Text] [Related]
40. Comparative Effectiveness Trial for Diabetic Macular Edema: Three Comparisons for the Price of 1 Study From the Diabetic Retinopathy Clinical Research Network.
Jampol LM; Glassman AR; Bressler NM
JAMA Ophthalmol; 2015 Sep; 133(9):983-4. PubMed ID: 26087135
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
